Alberico Catapano: The Role of Triglyceride Variability and the AIFA Reimbursement Gap
Alberico Catapano, Professor at Multimedica IRCCS, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Nutrition, Metabolism and Cardiovascular Diseases, adding:
“Pleased to share our latest real-world study on secondary cardiovascular prevention after acute coronary syndrome (ACS).
Despite intensive LDL-C lowering, residual cardiovascular risk remains substantial.
In our cohort of post-ACS patients, we found that:
Triglyceride variability, not absolute triglyceride levels, was independently associated with recurrent ischemic events over 12 months.
A striking gap exists between the European Medicines Agency (EMA) indication and the Italian Medicines Agency (AIFA) reimbursement criteria for icosapent ethyl (IPE): while several patients met the EMA eligibility criteria, almost none qualified for reimbursement under current AIFA rules.
These findings highlight an important opportunity to improve secondary prevention by aligning reimbursement policies with the available evidence, potentially enhancing patient outcomes while remaining cost-effective.”
Title: European Medicines Agency versus Italian Medicines Agency indications for icosapent ethyl: a long and winding road
Authors: Gavino Casu, Chiara Idini, Alberto Santoru, Giuseppe Serra, Ferruccio Bilotta, Carlo Poddighe, Pierluigi Merella, Valentina De Murtas, Federica Rubbino, Valentina Micheluzzi, Alberico L. Catapano
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 9, 2026, 11:22Saqib Ullah: Why Do Red Blood Cells Autoagglutinate
-
Aug 9, 2026, 11:06Oumayma Mnafe: ThroLy and IMPEDE VTE Scores in Hematologic Malignancies
-
Aug 9, 2026, 10:06Care Shouldn’t Depend on Where You Live – National Bleeding Disorders Foundation
-
Aug 9, 2026, 10:01Irma Bagdoniene: Plaque Stability and the Importance of LDL Lowering
-
Aug 9, 2026, 09:49Rana Al-Dhalaan: New Study Examines Viral Infections in Blood Donors
-
Aug 9, 2026, 09:29Michael Wilkinson: How Lp(a) Shapes Coronary Plaque and Cardiovascular Risk
-
Aug 9, 2026, 09:16Preparing for Gene Therapy Starts with Understanding Immunity – WFH
-
Aug 9, 2026, 08:46Christina Pohlman: Uncovering the Autoantibodies Behind APS
-
Aug 9, 2026, 08:39Alejandro González Veliz: The Future of Cardiogenic Shock Lies in Precision Medicine